Soo-Zin Kim

发表

Daxx overexpression in T-lymphoblastic Jurkat cells enhances caspase-dependent death receptor- and drug-induced apoptosis in distinct ways.

D. Nowak, S. Boehrer, D. Hoelzer, 2005, Cellular signalling.

Expression of ZAP-70 Protein Correlates with Disease Stage in Chronic Lymphocytic Leukemia and is Associated with, but not Generally Restricted to, Non-mutated Ig VH Status

L. Harder, S. Boehrer, D. Hoelzer, 2004, Leukemia & lymphoma.

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

M. Dreyling, J. Rech, M. Subklewe, 2010, Leukemia & lymphoma.

In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer.

J. Trojan, K. Engels, K. Chow, 2005, Anti-cancer drugs.

Expression of Daxx sensitizes Jurkat T-cells to the apoptosis-inducing effect of chemotherapeutic agents.

D. Nowak, S. Boehrer, D. Hoelzer, 2005, Pharmacological research.

Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia

S. Stilgenbauer, L. Bergmann, B. Schlegelberger, 2011, European journal of haematology.

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

M. Hansmann, S. Al-Batran, M. Welslau, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of HERC5 and its potential role in NSCLC progression

M. Esteller, A. Risch, M. Westphal, 2015, International journal of cancer.

Upon Drug-Induced Apoptosis in Lymphoma Cells X-linked Inhibitor of Apoptosis (XIAP) Translocates from the Cytosol to the Nucleus

D. Nowak, S. Boehrer, D. Hoelzer, 2004, Leukemia & lymphoma.

CD4+CD56+ Neoplasia: Clinical and Biological Features with Emphasis on Cytotoxic Drug-induced Apoptosis and Expression of Sialyl Lewis X

W. Sterry, T. Zollner, D. Hoelzer, 2003, Leukemia & lymphoma.

Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis

W. Hayes, R. Müller, F. Bauss, 2007, Journal of Bone and Mineral Metabolism.

In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.

Daniel Nowak, P. Atadja, D. Nowak, 2004, Biochemical pharmacology.

In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling.

D. Nowak, W. Hofmann, S. Boehrer, 2006, Pharmacological research.